Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: UPB

Upstream Bio, Inc.

Healthcare | Biotechnology

No licensed closing price on file for UPB. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-2.89

Upstream Bio, Inc. (NASDAQ: UPB) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 20:47 UTC.

What Upstream Bio, Inc. does

This clinical-stage biotechnology company develops verekitug, a monoclonal antibody designed to treat inflammatory diseases by targeting the TSLP receptor. The company is advancing verekitug through separate Phase 2 trials for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease, with plans to begin Phase 3 trials in severe asthma and chronic rhinosinusitis in the first quarter of 2027.

Summarized from Upstream Bio, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-2.89

Revenue, margins & earnings

FY2023: net loss $21M on revenue $2M$2MFY2023FY2024: net loss $63M on revenue $2M$2MFY2024FY2025: net loss $143M on revenue $3M$3MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-17
  • 2026-09-17General CounselSale-485$2.7K
  • 2026-09-17Chief Medical OfficerSale-895$4.9K
  • 2026-09-17Chief Executive OfficerSale-2,095$11.5K
Sign in to see all transactions →

Company news

View all →

Questions this page answers

What does Upstream Bio, Inc. do?

This clinical-stage biotechnology company develops verekitug, a monoclonal antibody designed to treat inflammatory diseases by targeting the TSLP receptor.

When did UPB last file with the SEC?

Upstream Bio, Inc.'s most recent SEC filing on record is a 8-K filed 2026-09-01. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 20:47 UTC. This page is also available as JSON at /api/data?ticker=UPB and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for UPB and 5,000+ tickers.

Create a free account — keep UPB
For your agent
GET /api/data?ticker=UPB

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt